Internationally trained AI yields generalizable COVID lung catcher

NIH researchers have demonstrated the wide—potentially worldwide—applicability of a COVID-detecting AI system that was trained on chest CTs from four hospitals in three countries.

The deep learning technique was able to tell COVID pneumonia from pneumonias of other origins with close to 91% accuracy, 93% specificity and a false positive rate of 10%.

First author Stephanie Harmon, PhD, and colleagues trained their system on chest CTs from patients in China, Japan and Italy, then tested it on demographically mixed patient cases from the U.S. and elsewhere.

The study is running in Nature Communications.

“While CT imaging may not necessarily be actively used in the diagnosis and screening for COVID-19, this deep learning-based AI approach may serve as a standardized and objective tool to assist the assessment of imaging findings of COVID-19,” the researchers comment in their discussion section.

A blog post from Nvidia, which supplied the platform on which the team developed its models, notes that the system’s ableness in differentiating between various pneumonias could make it useful when flu season settles in this fall.  

Nvidia says subsequent models may include prognostics, resource allocation, point-of-care detection for isolation of asymptomatic patients or other applications.

Click here for the blog post and here for the full study.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.